• HIV infection:
    • 1 tab OD
  • HIV pre-exposure prophylaxis (PrEP):
    • 1 tab OD
  • Treatment of hepatitis B/HIV-1 co-infection (Off-label):
    • 1 tab OD
    • Part of multi-drug regimen
  • HIV post-exposure prophylaxis (PEP) (Off-label):
    • 1 tab OD
    • Part of multi-drug regimen

Tablet: 300mg/200mg

For pre-exposure prophylaxis, check HIV status before treatment start and every 3 months or upon diagnosis of other sexually transmitted infections

Emtricitabine: Nucleoside reverse transcriptase inhibitor (NRTI). Following phosphorylation, it interferes with HIV viral DNA polymerase and inhibits viral replication

Tenofovir: Nucleoside reverse transcriptase inhibitor (NRTI); Following hydrolysis and phosphorylation, it inhibits HIV-1 reverse transcriptase by competing with AMP as substrate

  • Diarrhea
  • Nausea & vomiting
  • Fatigue
  • Headache
  • Dizziness
  • Depression
  • Insomnia
  • Abnormal dreams
  • Rash
  • Hypercholesterolemia
  • Elevated Ck
  • Bone density loss
  • Hyperamylasemia
  • Anemia (peds patients)
  • URI
  • Anxiety
  • Arthralgia
  • Myalgia
  • Cough
  • Dyspepsia
  • Fever
  • Abdominal pain
  • Back pain
  • Paresthesia
  • Peripheral neuropathy
  • Pneumonia
  • Palmar-plantar hyperpigmentation
  • Hypertriglyceridemia
  • Elevated LFTs
  • Neutropenia
  • Hematuria
  • Hyperglycemia
  • Glycosuria
  • Hypersensitivity of class/components
  • Use as monotherapy in HIV-infected patients
  • Positive or unknown HBsAg status in HIV pre-exposure prophylaxis use
  • Positive or unknown HIV status in HIV pre-exposure prophylaxis use
  • CrCl <60 (HIV prophylaxis use)
  • Concurrent or recent nephrotoxic agent use

WARNING:

  • Severe acute HBV exacerbations in HBV/HIV co-infected patients when discontinuing emtricitabine or tenofovir
  • Drug-resistant HIV-1 variants have been identified with use of emtricitabine/tenofovir for a PrEP indication following undetected acute HIV infection
  • Lamivudine
  • Cidofovir

                          Drug Status

Availability Prescription only
Pregnancy Category B
Breastfeeding Contraindication
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Tavin EM 300mg/200mg Tablet 30’s Emcure Pharma Lazor Pharma
Tenofovir/Emtricitabine 300mg/200mg Tablet 30’s Mylan Labs C/O Surgilinks Ltd Surgilinks Ltd
Truvada 300mg/200mg Tablet 30’s Gilead Sciences Phillips Therapeutics